Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 8/20 | 0.64 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 2/20 | 0.35 |
| ▸ | MC5R | P33032 | 2/20 | 0.35 |
| ▸ | MC3R | P41968 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL867540 | 1.00 | GHSR (0.64) | GHSRPPARGPPARAMMP9MMP8 | |
| SCHEMBL867539 | 1.00 | GHSR (0.64) | GHSRPPARGPPARAMMP9MMP8 | |
| SCHEMBL6320645 | 0.93 | GHSR (0.66) | GHSRMMP9MMP8MC4RMC5R | |
| SCHEMBL6325612 | 0.93 | GHSR (0.66) | GHSRMMP9MMP8MC4RMC5R | |
| SCHEMBL6320638 | 0.93 | GHSR (0.66) | GHSRMMP9MMP8MC4RMC5R | |
| SCHEMBL14433216 | 0.93 | GHSR (0.66) | GHSRPPARGPPARAMMP9MMP8 | |
| SCHEMBL18472634 | 0.92 | GHSR (0.65) | GHSRMMP9MMP8MC4RMC5R | |
| SCHEMBL6424310 | 0.91 | GHSR (0.60) | GHSRPPARGPPARAMMP9MMP8 | |
| SCHEMBL14003462 | 0.90 | GHSR (0.62) | GHSRMMP9MMP8 | |
| SCHEMBL3267711 | 0.90 | GHSR (0.75) | GHSRMMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260077018-A1 | TREATMENT OF MILD TRAUMATIC BRAIN INJURY | OXEIA BIOPHARMACEUTICALS INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4583902-A2 | TREATMENT OF MILD TRAUMATIC BRAIN INJURY | Oxeia Biopharmaceuticals, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054875-A2 | TREATMENT OF MILD TRAUMATIC BRAIN INJURY | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20230330187-A1 | USE OF GHRELIN OR GHRELIN VARIANT FOR INCREASING DOSE INTENSITY OF CHEMOTHERAPEUTIC AGENTS IN PATIENTS WITH CANCER | OXEIA BIOPHARMACEUTICALS INC (US) | 2023-10-19 | — | — | US | disclosed |
| WO-2022226116-A1 | GHRELIN TREATMENT OF BRAIN DYSFUNCTION DUE TO VIRAL INFECTION | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077018-A1 | TREATMENT OF MILD TRAUMATIC BRAIN INJURY | CRH, MYO1G, GHRHR | GHSR 6/4885PPARG 845/4885PPARA 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.